{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:18:57Z","timestamp":1791206337029,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.thromres.2012.08.271","type":"journal-article","created":{"date-parts":[[2012,9,28]],"date-time":"2012-09-28T20:02:09Z","timestamp":1348862529000},"page":"S41-S43","source":"Crossref","is-referenced-by-count":7,"special_numbering":"S1","title":["What did we learn from new oral anticoagulant treatment?"],"prefix":"10.1016","volume":"130","author":[{"given":"Charles T.","family":"Esmon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2012.08.271_bb0005","series-title":"Waltham, MA: UpToDate","article-title":"Anticoagulants other than heparin and warfarin","author":"Leung","year":"2012"},{"key":"10.1016\/j.thromres.2012.08.271_bb0010","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1161\/CIRCULATIONAHA.109.853119","article-title":"New anticoagulants","volume":"121","author":"Eikelboom","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2012.08.271_bb0015","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1172\/JCI114723","article-title":"Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors","volume":"86","author":"Weitz","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.thromres.2012.08.271_bb0020","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1046\/j.1538-7836.2003.00254.x","article-title":"Factor Xa is highly protected from antithrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex","volume":"1","author":"Brufatto","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2012.08.271_bb0025","doi-asserted-by":"crossref","first-page":"6667","DOI":"10.1182\/blood-2011-07-364141","article-title":"Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo","volume":"118","author":"Yau","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2012.08.271_bb0030","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus Warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2012.08.271_bb0035","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus Warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2012.08.271_bb0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2012.08.271_bb0045","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1001\/archinternmed.2011.1721","article-title":"Dabigatran: do we have sufficient data: comment on \u201cDabigatran association with higher risk of acute coronary events\u201d","volume":"172","author":"Jacobs","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.thromres.2012.08.271_bb0050","doi-asserted-by":"crossref","first-page":"17132","DOI":"10.1016\/S0021-9258(17)44879-4","article-title":"Functional characterization of human platelet-released factor V and its activation by factor Xa and thrombin","volume":"265","author":"Monkovic","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1016\/j.thromres.2012.08.271_bb0055","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.107.019083","article-title":"The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans","volume":"36","author":"Blech","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.thromres.2012.08.271_bb0060","author":"Drugs.com [internet]"},{"key":"10.1016\/j.thromres.2012.08.271_bb0065","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.2215\/CJN.00770208","article-title":"Vitamin K-dependent proteins, Warfarin, and vascular calcification","volume":"3","author":"Danziger","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.thromres.2012.08.271_bb0070","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2012.08.271_bb0075","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after knee arthroplasty (RECORD4): a randomized trial","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2012.08.271_bb0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomized, double-blind, phase II trial","volume":"374","author":"Mega","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2012.08.271_bb0085","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus randomized, double-blind, non-inferiority trial","volume":"370","author":"Eriksson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2012.08.271_bb0090","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatron versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2012.08.271_bb0095","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/j.1538-7836.2005.01374.x","article-title":"New anticoagulants","volume":"3","author":"Weitz","year":"2005","journal-title":"J Thromb Haemost"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384812006433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384812006433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T13:45:00Z","timestamp":1643463900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384812006433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":19,"alternative-id":["S0049384812006433"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2012.08.271","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}